Post-COVID-19 asthenic syndrome – DocWire News

This article was originally published here

Zh Nevrol Psikhiatr Im S S Korsakova. 2021;121(4):25-30. doi: 10.17116/jnevro202112104125.

ABSTRACT

OBJECTIVE: To study the features of asthenic syndrome and the possibilities of its therapy in patients in the post-covid period.

MATERIAL AND METHODS: The study included 129 patients with an average age of 49.88.9 years who had undergone COVID-19 using a continuous sample method. Patients for the study were selected at the clinical bases of outpatient clinics in Samara (Russia) in July-August 2020. All patients signed an informed consent form prior to enrollment. Patients were randomized into two groups: in the main group (n=64), ethylmethylhydroxypyridine succinate (Neurox) was prescribed 1 tablet (125 mg) 3 times a day for 4 weeks; in the comparison group (n=65), medical drugs (MD) did not contain substances from the pharmacological group related to antihypoxants/antioxidants/nootropics. Three visits (V) were conducted: the first (V1) the period of inclusion, the second (V2) after 14 days, the third (V3) on the 28th day from the start of therapy. The dynamics of the general state (weakness, fatigue, concentration, dizziness, headache, sleep disorders) were evaluated on a visual-analog scale (VAS), the assessment of the subjective feeling of severity of asthenia (fatigue, physical and mental fatigue, decreased motivation and activity) on Multidimensional Fatigue Inventory (MFI-20), cognitive functions on Mini-Mental State Examination (MMSE), vegetative tone according to the Kerdo index.

RESULTS: At the end of the study (V3), statistically significant changes in indicators (VAS, MFI-20) were obtained only in the main group patients; no statistically significant differences were obtained for the Kerdo index. Analysis of the MMSE data revealed a decrease in cognitive functions in both groups, which may be associated with pseudocognitive deficits due to asthenia.

CONCLUSIONS: We have obtained evidence of a high incidence of asthenic syndrome after COVID-19. Against the background of taking Neurox, there was a decrease in the severity and expression of asthenia symptoms.

PMID:34037351 | DOI:10.17116/jnevro202112104125

See the original post here:

Post-COVID-19 asthenic syndrome - DocWire News